Cellectis SA - Company Profile

Powered by

All the data and insights you need on Cellectis SA in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Cellectis SA Strategy Report

  • Understand Cellectis SA position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Cellectis SA: Overview

Select Item

Cellectis SA (Cellectis), operates as a clinical-stage biopharmaceutical company. It carries out research, develop and commercialize gene editing technology. The company’s pipeline products include UCART22, UCART123, UCART20x22, ALLO-501A 1, ALLO-715 3, ALLO-605 3, ALLO-316 4. z Its pipeline candidates treat Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Large B-cell Lymphoma, Multiple Myeloma, Multiple Myeloma, Renal Cell Carcinoma. Cellectis’s pioneer, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and eradicate cancer cells. It works in partnership with Allogene Therapeutics, Servier, Iovance Biotherapeutics, Inc, Cytovia Therapeutics, Inc., It operates in New York and Paris. Cellectis is headquartered in Paris, France.

 Gain a 360-degree view of Cellectis SA and make more informed decisions for your business Gain a 360-degree view of Cellectis SA and make more informed decisions for your business Find out more
Headquarters France
Address 8, Rue De La Croix Jarry, Paris, Ile-de-France, 75013
Website www.cellectis.com
Telephone 33 1 81691600
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange ALCLS (EPA)
Revenue (2021) $25.7M -33.3% (2021 vs 2020)
EPS XYZ
Net Income (2021) XYZ 7.1% (2021 vs 2020)
Market Cap* $184.6M
Net Profit Margin (2021) XYZ -39.5% (2021 vs 2020)
   
* As of and is in US$
View Cellectis SA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Cellectis SA premium industry data and analytics

30+

Pipeline Drugs

Identify which of Cellectis SA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Catalyst Calendar

Proactively evaluate Cellectis SA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

9

Clinical Trials

Determine Cellectis SA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

8

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Cellectis SA’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Services
Pipeline Research and Development
Hematopoietic Tumors: Gene Editing
UCARTMESO Immuno-Oncology
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Cellectis SA portfolio and identify potential areas for collaboration Understand Cellectis SA portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In April, the company entered into warrant agreement with the European Investment Bank related to credit facility agreement and announced the drawdown of the first tranche of EUR20 million.
2023 New Products/Services In February, the company announced the launch of a global offering of US$22 million of its American Depositary Shares.
2022 Contracts/Agreements In December, the company entered into an agreement with Primera Therapeutics, Inc. to work collaboratively to edit mutations in the mitochondrial DNA in vivo to treat the root cause of associated diseases.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Cellectis SA Genfit SA Median Technologies SA IntegraGen SA ABIONYX Pharma SA
Headquarters France France France France France
City Paris Loos Valbonne Evry Balma
State/Province Ile-de-France Bretagne Ile-de-France Centre Haute Normandie
No. of Employees - 159 233 57 63
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Andre Choulika, Ph.D. Director; Chief Executive Officer Executive Board 1999 -
David Sourdive, Ph.D. Executive Vice President; Director Executive Board 2000 -
Jean-Pierre Garnier, Ph.D. Chairman Non Executive Board 2020 -
Rainer Boehm, MD Director Non Executive Board - -
Donald A. Bergstrom, M.D., Ph.D Director Non Executive Board - -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Cellectis SA key executives to enhance your sales strategy Gain insight into Cellectis SA key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Start of HubSpot Embed Code End of HubSpot Embed Code